Clinical Trial Update: A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women [Phase 1]

View source ↗

Summary

A Phase 1 trial comparing two different formulations of Blosozumab (LY2541546) in postmenopausal women with osteoporosis was terminated, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Blosozumab (blosozumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Osteoporosis, Postmenopausal | Phase 1 | Status: TERMINATED | Results posted: 2019-01-22